Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

USPH vs PDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

USPH Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

USPH Overall Winner 6-Pillar Tally: USPH 5 – 0 PDX (1 Tie) Matrix Metrics: USPH 8 – 2 PDX

As of Nov 16, 2026, US Physical Therapy Inc (USPH) is the stronger overall head-to-head candidate over PIMCO Dynamic Income Strategy Fund (PDX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). USPH carries a Unified Composite Score of 31.8/100 (SELL) at $99.55 (29.6x Forward P/E, 10.2% operating margin), whereas PDX carries 45.3/100 (HOLD) at $20.06 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While PDX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. USPH 31.8/100 SELL), USPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+13.1% vs. N/A YoY).
  • Technical & Structure Timing Caution: USPH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.8); meanwhile PDX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About USPH vs PDX
USPH NYSE Head-to-Head Winner
US Physical Therapy Inc
Services-Health Services
$99.55
-0.05% 1D
Market Cap $1.5B
TTM Revenue $830M
Forward P/E 29.6x
Beta / 30D Vol 0.14β · 42% Vol
Unified Composite Score
31.8 / 100 SELL
Tech 50.0 Fund 25.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.2% over 20 days), RSI 72
RSI-14: 71.8 · SMA20: $91.84 · SMA50: $86.65
PDX NYSE
PIMCO Dynamic Income Strategy Fund
Institutional Equity
$20.06
-0.5% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.19β · 16% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 41.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.4%) with fading momentum, RSI 41
RSI-14: 40.7 · SMA20: $20.47 · SMA50: $20.59

6-Pillar Scorecard Institutional Category Breakdown (USPH 5 – 0 PDX)

Columns: Metric · USPH · PDX
1. Valuation Multiples USPH
Forward P/E 29.6x N/M
Trailing P/E 32.9x N/M
PEG Ratio 3.29x N/M
EV / Revenue 1.8x N/M
2. Growth & Scale USPH
Revenue Growth (YoY) +13.1% N/A
Earnings Growth (YoY) -56.5% N/A
TTM Revenue (USD) $830M N/A
Market Cap $1.5B $1.1B
3. Profitability & Quality USPH
Gross Margin 21.6% N/A
Operating Margin 10.2% N/A
Net Profit Margin 3.6% N/A
Return on Equity (ROE) 6.3% N/A
4. Balance Sheet & Cash Flow USPH
Cash Generation (TTM) $107M EBITDA N/A
Cash Flow Margin 12.9% EBITDA Mgn N/A
Net Cash / Leverage $28.76 Book/Sh · 6.3% ROE N/A ROE
Dividend Yield 1.86% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 35.3% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat USPH
OpEx & R&D Intensity 11.4% of Rev ($95M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: USPH (8) vs PDX (2)
Institutional Metric USPH PDX Criterion Row Edge
Market Capitalization
Scale
$1.5B $1.1B Larger Scale USPH
Trailing P/E Ratio
Valuation
32.9x N/M Lower Multiple USPH
Forward P/E Ratio
Valuation
29.6x N/M Lower Multiple USPH
Revenue Growth (YoY)
Growth
+13.1% N/A Higher Growth USPH
Operating Margin (TTM)
Profitability
10.2% N/A Higher Margin USPH
Net Profit Margin
Profitability
3.6% N/A Higher Margin USPH
Return on Equity (ROE)
Capital Efficiency
6.3% N/A Higher ROE USPH
52-Week Range Position
Momentum
95% ($58–$102) 42% ($18–$22) Stronger Trend USPH
Beta / 30D Volatility
Risk Regime
0.14β · 42% Vol 0.19β · 16% Vol Lower Realized Risk PDX
Unified Institutional Score
Composite Signal
31.8 / 100 (SELL) 45.3 / 100 (HOLD) Higher Composite PDX
Trailing 12M Revenue (USD)
Operating Scale
$830M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.29x PEG · 1.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$107M EBITDA ($28.76 Book/Sh · 6.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon USPH +15.95 pp
USPH: +16.15% · PDX: +0.2%
3M Horizon USPH +34.98 pp
USPH: +27.29% · PDX: -7.69%
6M Horizon USPH +60.19 pp
USPH: +53.06% · PDX: -7.13%
1Y Horizon USPH +47.47 pp
USPH: +39.78% · PDX: -7.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on USPH vs PDX. Trailing 12-month operating profitability (USPH 10.2% vs PDX N/A) and valuation multiples (USPH 29.6x vs PDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

USPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$830M
Gross Margin21.6%
Op. Margin10.2%
ROE / Fwd P/E6.3% · 29.6x
PDX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
USPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 35.3%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact USPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PDX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
USPH Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.5B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 11.4% of Rev ($95M)
90D Engineering Disclosures 0 Published
PDX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $1.1B market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ USPH vs PDX Key Questions & Quantitative Answers

As of Nov 16, 2026, US Physical Therapy Inc (USPH) is the stronger overall head-to-head candidate over PIMCO Dynamic Income Strategy Fund (PDX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). USPH carries a Unified Composite Score of 31.8/100 (SELL) at $99.55 (29.6x Forward P/E, 10.2% operating margin), whereas PDX carries 45.3/100 (HOLD) at $20.06 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While PDX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. USPH 31.8/100 SELL), USPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+13.1% vs. N/A YoY). Technical & Structure Timing Caution: USPH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.8); meanwhile PDX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

USPH leads the Growth & Scale pillar: USPH posts +13.1% YoY revenue growth and -56.5% YoY earnings growth on $830M TTM revenue (21.6% gross margin, 10.2% operating margin), compared with PDX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, USPH generates $830M in USD-normalized revenue versus N/A for PDX. In operating R&D and SG&A reinvestment, USPH deploys 11.4% of Rev ($95M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PDX.

USPH screens cheaper on headline valuation multiples. USPH trades at 29.6x Forward P/E, 32.9x Trailing P/E, 3.29x PEG, and 1.8x EV/Revenue (12.9% EBITDA margin), whereas PDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against USPH (6.3% ROE) versus PDX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, USPH carries 35.3% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 42% Vol realized risk). By comparison, PDX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 16% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.